{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:10:09Z","timestamp":1794276609021,"version":"4.9.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Visceral leishmaniasis affects 200\u2013400 thousands people annually worldwide. For last few decades, there has been a steady decline in the response to pentavalent antimonial (Sb<jats:sup>v<\/jats:sup>), the drug that has been used for treating visceral leishmaniasis for almost a century. Oral miltefosine and amphotericin B are alternative drugs being been used in the treatment of leishmaniasis in children. Liposomal amphotericin B has the advantage over conventional amphotericin B is that higher doses can be given with fewer adverse effects. Liposomal amphotericin B in combination with other drugs is the preferred treatment option globally especially in Indian subcontinent. Combination therapy with multiple drugs should undergo larger clinical trials in children as these will shorten the duration of therapy, improve compliance and decrease both toxicity and drug resistance.<\/jats:p>","DOI":"10.1097\/inf.0000000000001885","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T17:07:25Z","timestamp":1514394445000},"page":"492-494","source":"Crossref","is-referenced-by-count":26,"title":["Visceral Leishmaniasis\u2014Optimum Treatment Options in Children"],"prefix":"10.1097","volume":"37","author":[{"given":"Shyam","family":"Sundar","sequence":"first","affiliation":[{"name":"Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence.","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0035-9203(97)90516-2","article-title":"A comparison of intercostal and abdominal routes of splenic aspiration and bone marrow aspiration in the diagnosis of visceral leishmaniasis.","volume":"91","author":"Thakur","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India.","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis.","volume":"43","author":"Bern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India.","volume":"356","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.","volume":"6","author":"Musa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/cid\/cir521","article-title":"Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.","volume":"53","author":"Sinha","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jac\/dkh084","article-title":"Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.","volume":"53","author":"Lopez-Velez","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/clinids\/19.6.1034","article-title":"Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis.","volume":"19","author":"Sherwood","year":"1994","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201805000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:34:46Z","timestamp":1694558086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201805000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001885","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}